AstraZeneca Strikes Another Collaboration with Daichi Sankyo
AstraZeneca plc (NYSE: AZN) has struck a new global development and commercialization agreement with Daiichi Sankyo Company (OTCMKTS: SKYF) that could be worth up to $6 billion. The agreement focuses on DS-1062, Daiichi Sankyo’s proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), and potential new medicine for the treatment of multiple tumor types. AstraZeneca will pay $1 billion in staged payments over 24 months, and up to $5 billion for the successful achievement of regulatory approvals and sales-related milestones. The companies will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain... Read More »
Sanofi Inks New Licensing Deal
Just weeks following its agreement with Translate Bio (NASDAQ: TBIO) for COVID-19 vaccine development, Sanofi (NYSE: SNY) has a new agreement with Kymera Therapeutics Inc. Sanofi and Kymera are signing a multi-program collaboration to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. IRAK4 is believed to play a key role in multiple immune-inflammatory diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Kymera will receive $150 million in cash upfront and may receive more than $2 billion in potential development, regulatory and sales milestones, as well as significant... Read More »
Sanofi Pasteur Jumps Into the COVID-19 Vaccine Race
Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY) has expanded its partnership with Translate Bio (NASDAQ: TBIO ) to produce a COVID-19 vaccine. The two companies are pursuing novel mRNA vaccines aimed at broadly addressing current and future infectious diseases, evaluating multiple COVID-19 vaccine candidates. They hope to conduct human clinical trials in Q4:2020 but are also advancing an mRNA vaccine development candidate against influenza through preclinical studies with clinical trial initiation anticipated in mid-year 2021. The original agreement dates back to 2018, when Translate Bio and Sanofi Pasteur entered into a collaboration and exclusive license agreement to develop... Read More »
AbbVie and Genmab Sign Major New Oncology Deal
AbbVie Inc. (NYSE: ABBV) announced on June 10 a broad oncology collaboration with Denmark-based Genmab A/S (NASDAQ: GMAB). The two firms are teaming up to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product candidates. AbbVie and Genmab are also starting a discovery research collaboration for future differentiated antibody therapeutics for cancer, including epcoritamab, a bispecific antibody created using Genmab’s proprietary DuoBody technology. AbbVie will pay Genmab $750 million upfront, with total potential development, regulatory and sales milestone payments of up to $3.15 billion, as well as tiered royalties between... Read More »
Gilead Signs New Immunotherapy Partnership
Gilead Sciences, Inc. (NASDAQ: GILD), just a few months after its $4.9 billion purchase of Forty Seven, Inc. (NASDAQ: FTSV), has signed a 10-year partnership agreement to co-develop and co-commercialize next generation cancer immunotherapy with Arcus Biosciences (NYSE: RCUS). Gilead will provide $175 million upfront, a $200 million equity investment, and more than $1.6 billion in potential R&D funding. The deal includes immediate rights to zimberelimab, an investigational anti-PD-1 monoclonal antibody, as well as the right to opt-in to all other current Arcus clinical candidates. Arcus is eligible to receive up to $1.225 billion in opt-in and milestone payments with respect to its... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
